DE69637391D1 - Modifizierte myelin proteinmoleküle - Google Patents

Modifizierte myelin proteinmoleküle

Info

Publication number
DE69637391D1
DE69637391D1 DE69637391T DE69637391T DE69637391D1 DE 69637391 D1 DE69637391 D1 DE 69637391D1 DE 69637391 T DE69637391 T DE 69637391T DE 69637391 T DE69637391 T DE 69637391T DE 69637391 D1 DE69637391 D1 DE 69637391D1
Authority
DE
Germany
Prior art keywords
polypeptides
plp
useful
modified
mbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637391T
Other languages
English (en)
Other versions
DE69637391T2 (de
Inventor
John P Mueller
Michael J Lenardo
Henry F Mcfarland
Louis Matis
Eileen Elliott Mueller
Steven H Nye
Clara M Pelfrey
Stephen P Squinto
James A Wilkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Alexion Pharmaceuticals Inc
Original Assignee
US Department of Health and Human Services
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,644 external-priority patent/US7041503B2/en
Application filed by US Department of Health and Human Services, Alexion Pharmaceuticals Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69637391D1 publication Critical patent/DE69637391D1/de
Publication of DE69637391T2 publication Critical patent/DE69637391T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69637391T 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle Expired - Lifetime DE69637391T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43164895A 1995-05-02 1995-05-02
US08/431,644 US7041503B2 (en) 1995-05-02 1995-05-02 Modified myelin basic protein molecules
US431644 1995-05-02
US431648 1995-05-02
US48211495A 1995-06-07 1995-06-07
US482114 1995-06-07
PCT/US1996/005611 WO1996034622A1 (en) 1995-05-02 1996-04-22 Modified myelin protein molecules

Publications (2)

Publication Number Publication Date
DE69637391D1 true DE69637391D1 (de) 2008-02-14
DE69637391T2 DE69637391T2 (de) 2008-08-14

Family

ID=27411744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637391T Expired - Lifetime DE69637391T2 (de) 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle

Country Status (8)

Country Link
EP (1) EP0830139B1 (de)
JP (1) JPH11511650A (de)
KR (1) KR100682350B1 (de)
AT (1) ATE382366T1 (de)
AU (1) AU5565896A (de)
CA (1) CA2218858A1 (de)
DE (1) DE69637391T2 (de)
WO (1) WO1996034622A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1522591A3 (de) * 1997-02-25 2005-08-17 GTC Biotherapeutics, Inc. Transgen produzierte nicht-sekretierte Proteine
EP0973934A4 (de) * 1997-02-25 2003-02-05 Genzyme Transgenics Corp Transgen produzierte nicht-sekretierte proteine.
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸
CN1301752A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——plp蛋白10和编码这种多肽的多核苷酸
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP2292637B1 (de) 2002-09-06 2016-01-06 Genentech, Inc. Verfahren zur Proteinextraktion
WO2004060910A2 (en) * 2002-12-16 2004-07-22 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
WO2005080985A2 (en) * 2004-02-18 2005-09-01 Enteron Limited Partnership Methods and compositions for detecting and treating autoimmune diseases
KR100791996B1 (ko) * 2006-08-02 2008-01-04 고려대학교 산학협력단 미엘린 염기성 폴리펩타이드를 분비하는 형질전환 미생물을함유하는 자가면역질환 치료용 조성물
WO2016145086A1 (en) * 2015-03-09 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960705038A (ko) * 1993-09-03 1996-10-09 스테시 엘. 채닝 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)

Also Published As

Publication number Publication date
WO1996034622A1 (en) 1996-11-07
KR100682350B1 (ko) 2008-11-06
ATE382366T1 (de) 2008-01-15
DE69637391T2 (de) 2008-08-14
JPH11511650A (ja) 1999-10-12
KR19990008329A (ko) 1999-01-25
MX9708418A (es) 1998-10-31
CA2218858A1 (en) 1996-11-07
AU5565896A (en) 1996-11-21
EP0830139A4 (de) 2001-10-10
EP0830139B1 (de) 2008-01-02
EP0830139A1 (de) 1998-03-25

Similar Documents

Publication Publication Date Title
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
NO982794D0 (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
FR2751986B1 (fr) Gene implique dans le cadasil, methode de diagnostic et application therapeutique
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
DE60142693D1 (de) Arzneimittel für herzversagen
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
PT948604E (pt) Produtos e metodos relacionados com pyk2
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
BR0009805A (pt) Mutações de enos úteis para terapia genética e rastreamento terapêutico
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69329656T2 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
ATE317021T1 (de) Antisense modulierung von lfa-3
DE69734890D1 (de) Rdgb-proteine
TR199901385T2 (xx) Piperidin t�revleri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition